Drugs / Rhodiola rosea
Rhodiola rosea
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04218916 | Jan 2020 → Jan 2021 | coronary microvascular disorder | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01098318 | Jun 2010 → Jul 2013 | depressive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06889584 | Feb → Dec 2025 | — | University of South Carolina | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rhodiola rosea | “Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy.” NCT01098318 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “R. rosea belongs to the family Crassulaceae, and has a long history as a folk remedy for enhancing physical and emotional endurance.” NCT01098318 ↗ |